Robin Van Der Meulen


  • The Legal 500 “Next Generation Partner” (2021-2022)
  • Chambers USA: “Up and Coming” (2021-2023)
  • Benchmark Litigation “Future Star” (2021-2024)
  • Benchmark’s “40 & Under Hot List” (2021)
  • Euromoney’s Women in Business Law Awards: Antitrust and Competition Lawyer of the Year Finalist (2021)
  • The Best Lawyers in America®: Antitrust Law (2022-2024)
  • Chair of the Antitrust Law Section of the New York State Bar Association (2024)



Robin van der Meulen is a partner in Scott+Scott’s New York office. She has 15 years of experience litigating a wide variety of antitrust matters, including price-fixing, monopolization, benchmark and commodities manipulation, pay-for-delay agreements, and other anticompetitive practices. Robin has served as lead or co-lead counsel for end-payor plaintiffs in several pay-for-delay antitrust class actions and recently recovered $30 million for end-payor plaintiffs in the Novartis and Par Antitrust Litigation, a pay-for-delay case relating to the hypertension drug Exforge. In addition, Robin recently led a no-poach case alleging that companies in the aerospace industry conspired to restrict competition in the recruitment and hiring of engineers and other skilled workers.

The Legal 500 recommends Robin for excellence in the field of Antitrust Civil Litigation and Class Actions, describing her as “persistent, persuasive, and well-respected by peers and opponents alike.” She has also been selected to Benchmark’s “40 & Under Hot List” as one of “the best and brightest law firm partners” and someone who is “ready to take the reins.” Chambers highlights that “Robin has great presence. She is deliberative, prudent and smart.”

Robin also devotes substantial time as a leader in the antitrust bar. She currently serves as the Chair of the Antitrust Law Section of the New York State Bar Association. Robin is also co-chair of the Insurance and Financial Services Committee of the Antitrust Section of the American Bar Association (ABA). And she was previously a vice chair of the Antitrust Section’s Health Care & Pharmaceutical Committee of the ABA.

Prior to joining Scott+Scott, Robin was a partner in a nationally recognized antitrust practice group and before that an associate at Willkie Farr & Gallagher LLP, where she practiced antitrust and commercial litigation. She also served as a judicial intern in the United States Bankruptcy Court for the Eastern District of New York for Judge Elizabeth S. Stong. While in college, Robin was a member of Columbia University’s Division I Track and Field team, specializing in hurdles and sprints.



  • Borozny, et al. v. RTX, Pratt & Whitney Division, et al., No. 3:21-cv-01657 (D. Conn.)
  • In re Novartis and Par Antitrust Litigation (Exforge), No. 1:18-cv-04361 (S.D.N.Y.)
  • In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2:16-md-02724 (E.D. Pa.)
  • Alaska Electrical Pension Fund v. Bank of America (ISDAFix), 1:14-cv-07126 (S.D.N.Y)